(Toronto) Universal Screening for Lynch Syndrome in Women With Endometrial & Non-Serous Ovarian Cancer - clinicaltrial.gov

Full Text View 
 

Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer (LS2) (Lynch Syndrome 2)

This study is not yet open for participant recruitment. (see Contacts and Locations)

Verified July 2015 by University Health Network, Toronto 

 

Sponsor:

University Health Network, Toronto

Collaborators:

Mount Sinai Hospital, Canada

Sunnybrook Health Sciences Centre

Hamilton Health Sciences Corporation

Ryerson University

University of Toronto

Information provided by (Responsible Party):

University Health Network, Toronto

ClinicalTrials.gov Identifier:

NCT02494791

First received: July 7, 2015

Last updated: NA

Last verified: July 2015

History: No changes posted

• Full Text View
• Tabular View
• No Study Results Posted
• Disclaimer
• How to Read a Study Record

  Purpose

This study will maximize identification of women with Lynch Syndrome using an enhanced screening strategy to identify those at risk. These women will be referred to genetic counselling for testing and those found to have Lynch Syndrome will be asked to invite first degree relatives to participate and undergo genetic testing for Lynch Syndrome. Screening guidelines and risk reducing surgery options for participants found to have Lynch Syndrome will be reinforced by the study and adherence to these guidelines will be assessed annually for ten years following Lynch Syndrome diagnosis to assess the impact and cost-effectiveness of this enhanced screening approach.

Condition	Intervention
Lynch Syndrome Endometrial Neoplasms Ovarian Neoplasms Colorectal Neoplasms	Behavioral: Questionnaire, Educational Material

Study Type:	Observational
Study Design:	Time Perspective: Prospective